{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.9","value":"9.5"},{"groupId":"OG001","spread":"11.2","value":"10.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2331"},{"groupId":"OG001","value":"2335"}],"units":"Participants"}],"title":"Baseline:Systemic SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.5","value":"21.1"},{"groupId":"OG001","spread":"17.9","value":"21.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2071"},{"groupId":"OG001","value":"2107"}],"units":"Participants"}],"title":"Change at Week 13: Systemic SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.2","value":"9.2"},{"groupId":"OG001","spread":"14.2","value":"8.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2043"},{"groupId":"OG001","value":"2072"}],"units":"Participants"}],"title":"Change at Week 25: Systemic SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.4","value":"8.3"},{"groupId":"OG001","spread":"14.8","value":"7.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2258"},{"groupId":"OG001","value":"2280"}],"units":"Participants"}],"title":"Change at EOT: Systemic SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.8","value":"4.4"},{"groupId":"OG001","spread":"13.4","value":"5.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1909"},{"groupId":"OG001","value":"1912"}],"units":"Participants"}],"title":"Change at FU Month 18: Systemic SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.2","value":"4.1"},{"groupId":"OG001","spread":"13.7","value":"4.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1860"},{"groupId":"OG001","value":"1871"}],"units":"Participants"}],"title":"Change at FU Month 24: Systemic SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.6","value":"4.5"},{"groupId":"OG001","spread":"13.8","value":"5.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1812"},{"groupId":"OG001","value":"1783"}],"units":"Participants"}],"title":"Change at FU Month 36: Systemic SE"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.8","value":"26.4"},{"groupId":"OG001","spread":"29.0","value":"22.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"340"}],"units":"Participants"}],"title":"Baseline: Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.6","value":"17.3"},{"groupId":"OG001","spread":"37.8","value":"21.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"206"}],"units":"Participants"}],"title":"Change at Week 13: Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"38.0","value":"8.3"},{"groupId":"OG001","spread":"38.4","value":"14.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"101"}],"units":"Participants"}],"title":"Change at Week 25: Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.1","value":"10.9"},{"groupId":"OG001","spread":"39.8","value":"17.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"297"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"title":"Change at EOT: Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"36.0","value":"-7.0"},{"groupId":"OG001","spread":"34.9","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"104"}],"units":"Participants"}],"title":"Change at FU Month 18: Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.3","value":"-4.1"},{"groupId":"OG001","spread":"36.0","value":"0.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"title":"Change at FU Month 24: Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.3","value":"-5.6"},{"groupId":"OG001","spread":"34.7","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Change at FU Month 36: Hair Loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.1","value":"21.6"},{"groupId":"OG001","spread":"19.2","value":"21.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2326"},{"groupId":"OG001","value":"2331"}],"units":"Participants"}],"title":"Baseline: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.8","value":"-4.7"},{"groupId":"OG001","spread":"21.5","value":"-2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2064"},{"groupId":"OG001","value":"2102"}],"units":"Participants"}],"title":"Change at Week 13: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.3","value":"-2.9"},{"groupId":"OG001","spread":"21.7","value":"-2.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2037"},{"groupId":"OG001","value":"2070"}],"units":"Participants"}],"title":"Change at Week 25: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.5","value":"-3.5"},{"groupId":"OG001","spread":"21.4","value":"-3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2251"},{"groupId":"OG001","value":"2275"}],"units":"Participants"}],"title":"Change at EOT: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.8","value":"-4.0"},{"groupId":"OG001","spread":"22.5","value":"-3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1903"},{"groupId":"OG001","value":"1913"}],"units":"Participants"}],"title":"Change at FU Month 18: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.6","value":"-5.1"},{"groupId":"OG001","spread":"22.3","value":"-5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1857"},{"groupId":"OG001","value":"1866"}],"units":"Participants"}],"title":"Change at FU Month 24: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.8","value":"-5.9"},{"groupId":"OG001","spread":"22.4","value":"-4.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1809"},{"groupId":"OG001","value":"1777"}],"units":"Participants"}],"title":"Change at FU Month 36: Arm Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.5","value":"19.5"},{"groupId":"OG001","spread":"17.7","value":"20.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2325"},{"groupId":"OG001","value":"2330"}],"units":"Participants"}],"title":"Baseline: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.4","value":"-5.0"},{"groupId":"OG001","spread":"18.0","value":"-5.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2063"},{"groupId":"OG001","value":"2102"}],"units":"Participants"}],"title":"Change at Week 13: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.7","value":"1.9"},{"groupId":"OG001","spread":"20.6","value":"-0.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2036"},{"groupId":"OG001","value":"2069"}],"units":"Participants"}],"title":"Change at Week 25: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.2","value":"-0.6"},{"groupId":"OG001","spread":"19.7","value":"-3.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2250"},{"groupId":"OG001","value":"2275"}],"units":"Participants"}],"title":"Change at EOT: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.7","value":"-3.0"},{"groupId":"OG001","spread":"18.8","value":"-5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1903"},{"groupId":"OG001","value":"1911"}],"units":"Participants"}],"title":"Change at FU Month 18: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.4","value":"-6.4"},{"groupId":"OG001","spread":"18.7","value":"-7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1857"},{"groupId":"OG001","value":"1865"}],"units":"Participants"}],"title":"Change at FU Month 24: Breast Symptoms"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.8","value":"-7.3"},{"groupId":"OG001","spread":"19.0","value":"-7.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1808"},{"groupId":"OG001","value":"1775"}],"units":"Participants"}],"title":"Change at FU Month 36: Breast Symptoms"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2331"},{"groupId":"OG001","value":"2335"}],"units":"Participants"}],"description":"EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective \\[FP\\]) and four symptom scales (systemic side effects \\[SE\\], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores averaged and transformed to 0-100 scale. High score for symptom scale indicated high level of symptomatology/problems/greater degree of symptoms. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).","id":"OG000","title":"Pertuzumab + Trastuzumab + Chemotherapy"},{"description":"Participants received placebo matched to pertuzumab IV Q3W and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m\\^2 + epirubicin 90-120 mg/m\\^2 or doxorubicin 50 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m\\^2 for 3 cycles, 75 mg/m\\^2 in first cycle and 100 mg/m\\^2 in subsequent cycles, or 75 mg/m\\^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m\\^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m\\^2 or epirubicin 90-120 mg/m\\^2 + cyclophosphamide 500-600 mg/m\\^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m\\^2 + carboplatin AUC 6 (up to 900 mg).","id":"OG001","title":"Placebo + Trastuzumab + Chemotherapy"}],"paramType":"MEAN","populationDescription":"ITT population. Overall number of participants analyzed=participants evaluable for this outcome measure. Number analyzed=participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 13, 25; EOT (28 days after the last dose, up to Week 56); FU Months 18, 24, 36","title":"Change From Baseline in EORTC QLQ-BR23 Symptom Scale Score","type":"SECONDARY","unitOfMeasure":"units on a scale"}